NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Viatris Inc. ("Viatris" or the "Company") (NASDAQ: VTRS) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Viatris investors who were adversely affected by alleged securities fraud between August 8, 2024 and February 26, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/viatris-inc-lawsuit-submissio ...

Core Viewpoint - A securities class action lawsuit has been filed against Viatris Inc. for allegedly misleading investors regarding the impact of a failed inspection at its Indore, India facility and a Warning Letter from the U.S. FDA, leading to a significant drop in stock price following the announcement of disappointing financial results [1][3]. Group 1: Lawsuit Details - The lawsuit covers purchasers of Viatris securities from August 8, 2024, to February 26, 2025, known as the "Class Period" [1]. - Investors learned of the misleading information on February 27, 2025, when Viatris announced its Q4 and full-year 2024 financial results, which included disappointing guidance for 2025 due to the expected financial impact from the Indore facility warning letter and import alert [3]. - Following this announcement, Viatris' stock price fell over 15%, dropping from $11.24 per share to $9.53 per share [3]. Group 2: Company Overview - Viatris is a healthcare company based in Canonsburg, PA, that supplies medicines to 1 billion patients globally [2]. - The company has faced scrutiny due to regulatory issues at its Indore facility, which have been highlighted in the lawsuit [3]. Group 3: Investor Information - Investors who purchased Viatris securities during the Class Period have until June 3, 2025, to seek appointment as a lead plaintiff representative of the class [2]. - A lead plaintiff acts on behalf of all class members in directing the litigation and is typically the investor or group of investors with the largest financial interest [4].

Core Viewpoint - A class action securities lawsuit has been filed against Viatris Inc. due to alleged securities fraud that negatively impacted investors between August 8, 2024, and February 26, 2025 [1] Group 1: Lawsuit Details - The lawsuit claims that Viatris misrepresented the implications of a warning letter from the FDA regarding its Indore, India facility, downplaying its significance as a "minor headwind" [2] - Following the announcement of disappointing financial results for Q4 and fiscal year 2024, Viatris' stock price dropped from $11.24 to $9.53 per share, a decline of approximately 15.21% in one day [2] Group 2: Investor Participation - Investors who suffered losses during the specified timeframe have until June 3, 2025, to request to be appointed as lead plaintiff, although participation in any recovery does not require this [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees [3] Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4]

NEW ORLEANS, April 17, 2025 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until June 3, 2025 to file lead plaintiff applications in a securities class action lawsuit against Viatris Inc. (“Viatris” or “the Company”) (NasdaqGS: VTRS), if they purchased the Company’s securities between August 8, 2024 and February 26, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Western District of Pennsylvan ...

NEW YORK, April 17, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Viatris Inc. (NASDAQ: VTRS).Shareholders who purchased shares of VTRS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/viatris-inc-loss-submission-form-2/?id=143351&from=4CLASS PERIOD: August 8, 2024 to Februar ...

Core Viewpoint - The Viatris class action lawsuit alleges that the company and its executives misrepresented the impact of regulatory issues on its financial outlook, leading to significant stock price declines following disappointing earnings guidance [3][4]. Group 1: Class Action Lawsuit Details - The class action lawsuit is titled Quinn v. Viatris Inc., and it involves purchasers of Viatris securities from August 8, 2024, to February 26, 2025, with a deadline of June 3, 2025, for lead plaintiff applications [1]. - The lawsuit claims that Viatris downplayed the ramifications of a failed FDA inspection at its Indore facility, which significantly affected its revenue outlook and growth projections [3]. - Following the announcement of disappointing financial results for Q4 and full fiscal year 2024, Viatris' stock price dropped by over 15% on February 27, 2025 [4]. Group 2: Company Background - Viatris is described as a global healthcare company facing challenges related to regulatory compliance and product manufacturing [2]. - The law firm Robbins Geller Rudman & Dowd LLP, which is leading the class action, has a strong track record in securities fraud litigation, having recovered over $2.5 billion for investors in 2024 alone [6].

PHILADELPHIA, April 15, 2025 (GLOBE NEWSWIRE) -- Berger Montague PC advises investors that a securities class action lawsuit has been filed against Viatris Inc. (“Viatris” or the “Company”) (NASDAQ: VTRS) on behalf of purchasers of Viatris securities between August 8, 2024 through February 26, 2025, inclusive (the “Class Period”). Investor Deadline: Investors who purchased or acquired Viatris securities during the Class Period may, no later than JUNE 3, 2025, seek to be appointed as a lead plaintiff represe ...

Core Insights - Lifecore Biomedical has appointed Thomas Salus as chief legal and administration officer and corporate secretary, bringing over 30 years of legal and management expertise, particularly in the life sciences industry [1][2][3] - Mr. Salus will oversee all legal activities and human resources, contributing to strategy development and corporate development focused on strategic alliances and partnerships [1][3] - The appointment is part of Lifecore's strategy to enhance corporate governance and SEC/Nasdaq reporting and compliance, aiming to streamline processes that impact performance [3] Company Overview - Lifecore Biomedical, Inc. is a fully integrated contract development and manufacturing organization (CDMO) specializing in the development, fill, and finish of sterile injectable pharmaceutical products [4] - The company has over 40 years of expertise in manufacturing premium, injectable-grade hyaluronic acid and partners with global and emerging biopharmaceutical and biotechnology companies across multiple therapeutic categories [4]

PITTSBURGH, April 14, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS) today announced that Hemanth J. Varghese has joined the Company as Chief Strategy Officer. Varghese will be a member of the Company's Executive Leadership Team.Varghese is an accomplished healthcare leader with more than 20 years of strategy, operations and corporate development experience. He brings broad experience leading growth initiatives and strategic transformations in diversified multi-national healthcare companies. Viatris A ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Viatris, Inc. due to allegations of violations of federal securities laws related to misleading statements and undisclosed information impacting the company's revenue outlook and growth [5][6]. Group 1: Legal Investigation and Class Action - The law firm is encouraging investors who suffered losses exceeding $100,000 in Viatris between August 8, 2024, and February 26, 2025, to discuss their legal options [1]. - A federal securities class action has been filed against Viatris, with a deadline of June 3, 2025, for investors to seek the role of lead plaintiff [3][8]. - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [4]. Group 2: Allegations Against Viatris - The complaint alleges that Viatris and its executives made false and misleading statements regarding the company's financial outlook and downplayed the significance of a failed FDA inspection at its Indore facility [5]. - The lawsuit claims that the impact of the failed inspection and subsequent remediation efforts significantly affected Viatris' projected fiscal year 2025 finances, particularly regarding the manufacturing and shipping of key products like Lenalidomide [5]. Group 3: Financial Impact and Stock Performance - On February 27, 2025, Viatris announced disappointing financial results for the fourth quarter and full fiscal year 2024, attributing below-expectation guidance to the impact of the Indore facility warning letter and import alert [6]. - Following this announcement, Viatris' stock price dropped from $11.24 per share on February 26, 2025, to $9.53 per share on February 27, 2025, marking a decline of approximately 15.21% in one day [7].